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The expression and function in growth and apoptosis of the renin–angiotensin system (RAS) was evaluated in human glioblastoma.
Renin and angiotensinogen (AGT) mRNAs and proteins were found by in situ hybridisation and immunohistochemistry in
glioblastoma cells. Angiotensinogen was present in glioblastoma cystic fluids. Thus, human glioblastoma cells produce renin and AGT
and secrete AGT. Human glioblastoma and glioblastoma cells expressed renin, AGT, renin receptor, AT2 and/or AT1 mRNAs and
proteins determined by RT–PCR and/or Western blotting, respectively. The function of the RAS in glioblastoma was studied using
human glioblastoma cells in culture. Angiotensinogen, des(Ang I)AGT, tetradecapaptide renin substrate (AGT1–14), Ang I, Ang II or
Ang III, added to glioblastoma cells in culture, did not modulate their proliferation, survival or death. Angiotensin-converting enzyme
inhibitors did not diminish glioblastoma cell proliferation. However, the addition of selective synthetic renin inhibitors to glioblastoma
cells decreased DNA synthesis and viable tumour cell number, and induced apoptosis. This effect was not counterbalanced by
concomitant addition of Ang II. In conclusion, the complete RAS is expressed by human glioblastomas and glioblastoma cells in
culture. Inhibition of renin in glioblastoma cells may be a potential approach to control glioblastoma cell proliferation and survival, and
glioblastoma progression in combination therapy.
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In addition to their functions in controlling vascular tone and
natriohydric balance, the components of the renin–angiotensin
system (RAS) may be involved in cell growth and survival.
Angiotensin peptides may promote cell growth, whereas angio-
tensinogen (AGT) was shown to inhibit vascular cell growth and
angiogenesis (Ce ´le ´rier et al, 2002). These functions may be of
particular importance in human disorders related to growth
dysfunctions, either increased proliferation such as cardiovascular
remodelling and cancer, or diminished proliferation such as
defects in tissue repair.
The RAS is composed of a precursor molecule, AGT, a peptide
related to the family of serine protease inhibitors (serpins), as the
unique substrate for the protease renin (EC 3.4.23.15). The
hydrolysis of AGT by renin is rate-limiting for the whole system
and results in the production of des(Ang I)-AGT and of the
vasoinactive peptide Ang I, which is converted to the vasoactive
peptides Ang II and Ang III by angiotensin-converting enzyme
(ACE) (EC 3.4.15.1) and aminopeptidase A (EC 3.4.11.7),
respectively. These peptides act on two membrane-bound recep-
tors (AT1 and AT2) belonging to the seven-transmembrane G-
protein-coupled receptor (GPCR) family. More recently, it has
been suggested that, in addition to the release of Ang I from AGT,
renin might act directly on cell function as a ligand for a cell-
membrane receptor, resulting in the phosphorylation of ERK
(extracellular regulated kinase) (Takahashi et al, 1985; Nguyen
et al, 1996, 2002). Inhibitors of the renin and ACE enzymes as well
as antagonists to the AT1 receptors have been developed in the
context of cardiovascular disorders.
The RAS is expressed independently of the circulating RAS in
normal nonvascular tissues (Inwang et al, 1997; Tahmasebi et al,
1998; Hirasawa et al, 2002), including the CNS (Milsted et al, 1990;
Humpel et al, 1994), where, in addition to regulating cardiovas-
cular functions (Morimoto et al, 2002), its role may include the
control of cell death and/or growth (Kakinuma et al, 1997). Renin-
secreting tumours of several nonrenal origins have been described
and the role of the RAS has been evaluated in a few situations in
human cancer. In breast cancer, Ang II increased integrin
expression (Berry et al, 2001) and Ang II exerted growth-
promoting effects via the AT1 receptor (De Paepe et al, 2001). In
a C6 glioblastoma rat model, losartan (AT1 antagonist) reduced
tumour growth, vascular density, cell proliferation and mitotic
index (Rivera et al, 2001). We have previously shown high
expression of ACE protein in human glioblastoma vessels;
however, inhibition of ACE did not modify the growth of an
experimental glioblastoma implanted in rat brains (Juillerat-
Jeanneret et al, 2000). The production of renin and AGT or a
Received 3 September 2003; revised 5 December 2003; accepted 15
December 2003
*Correspondence: Dr L Juillerat-Jeanneret;
E-mail: lucienne.juillerat@chuv.hospvd.ch
British Journal of Cancer (2004) 90, 1059–1068
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ypotential function of renin, angiotensins and/or AGT in these
tumours was not evaluated in these previous experiments.
Therefore, in the present study, we report the expression and
functions of renin, AGT and angiotensin peptides in human
glioblastoma tumours and human glioblastoma cells in culture.
MATERIAL AND METHODS
Human surgical specimens
Human astrocytoma and glioblastoma samples (grade II, n¼1,
grade III, n¼6; grade IV, n¼5) were retrospectively selected from
surgical diagnostic biopsies or subtotal resection specimens, either
fixed in 4% buffered paraformaldehyde and embedded in paraffin,
or frozen in liquid nitrogen and stored at  801C. Paraffin-
embedded samples were used for immunohistochemistry and in
situ hybridisation and frozen samples for Western blotting and
RT–PCR experiments. The fluid content of glioblastoma pseudo-
cysts (due to the absence of epithelial lining, the term cyst cannot
be used formally) was obtained at the time of surgery by aspiration
of the fluid, and stored at  801C. Plasma was obtained from
patients with various diseases and cerebrospinal fluids were
retrospectively selected from patients with brain tumours under-
going punctions for diagnostic purposes.
Immunohistochemistry
Paraffin-embedded sections (5mm thick) of human glioblastoma
were deparaffinised in xylene and isopropanol, and endogenous
peroxidase was inactivated in 3% hydrogen peroxide in methanol.
Sections were incubated with the antirenin 2D12/F37 and 4G1/F55
monoclonal antibodies, as previously described (Galen et al, 1984;
Juillerat-Jeanneret et al, 2000), anti-AGT (N-1345 and C-1350
(Ce ´le ´rier et al, 2000)), anti-des(Ang I)-AGT (D854 (Ce ´le ´rier et al,
2000)), and subsequently exposed to peroxidase-conjugated
secondary immunoglobulins. Peroxidase activity was visualised
using 0.035% diaminobenzidine (Fluka) as a chromogen, and
slides were counterstained with haematoxylin.
In situ hybridisation
In situ hybridisation for renin, ACE and AGT was performed
essentially as previously described (Sibony et al, 1995). Briefly,
paraffin sections (7mm) were deparaffinised, rehydrated, heated in
a microwave oven, and digested with proteinase K (Roche
Diagnostics) before hybridisation with the
35S-labelled riboprobes
(3–4 10
5cpmsection
 1). Hybridisation was performed over-
night at 501C and was followed by several washes and an RNAse
treatment to remove single-strand nonhybridised cRNA strands.
Sense probes were used as controls. Sections were exposed in the
dark, processed for autoradiography and counterstained with
toluidine blue. Observation was performed under dark field or
bright field illumination.
AGT concentration measurements
The concentration of AGT in glioblastoma ascitic fluids was
determined by measuring the production of Ang I concentrations
at 371C in the absence or presence of added renin, as previously
described (Ce ´le ´rier et al, 2002). AGT equivalents were calculated
from the Ang I generated from AGT present in the ascitic fluid.
RT–PCR and Western blotting determination of the
components of the RAS
Total RNA was isolated from cells in culture or from surgical
samples using the Trizol reagent (Gibco-BRL, Basel, Switzerland).
RT–PCR was performed according to standard procedures and 35
cycles, using primer sequences given in Table 1. Positive controls
were mRNAs extracted from normal human kidney, liver,
pulmonary artery or breast cancer. As controls for RNA quality,
amplification reactions were performed using pairs of primers
specific for glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
Egidy et al, 2000). Amplified transcripts were analysed on 2%
agarose gels.
Proteins were extracted from confluent layers of glioblastoma
cell cultures in 40mM HEPES pH 7.5 containing 100mM NaCl,
0.1mM EDTA, 100mM PMSF, 10% glycerol, 0.5% NP40, and the
extracts were submitted to electrophoresis. After transfer, the
membranes were probed using the F37 antirenin monoclonal
antibody (Galen et al, 1984), a kind gift of Sanofi-Pasteur,
Montpellier, polyclonal antirenin-receptor antibody (Nguyen
et al, 2002), polyclonal anti-AT1 and anti-AT2 (Santa-Cruz
Biotechnologies, Santa-Cruz, CA, USA) antibodies, and revealed
using the ECL detection kit (Amersham, UK).
Treatments of glioblastoma cell cultures
Human recombinant AGT or des(Ang I)AGT were obtained from
AGT-transfected CHO-cell supernatants, as previously described
(Ce ´le ´rier et al, 2002). CHO cells were grown in serum-free medium
(Ce ´le ´rier et al, 2000) and secreted 15mg AGT per litre of medium
in 24h. Mock-transfected cell supernatants were used as controls.
Experiments were performed in the presence or absence of FasL-
containing Neuro2A cell supernatants, as previously described
(Egidy et al, 2000; Peduto Eberl et al, 2000). Human renin
Table 1 Specific primers for the amplification of renin, renin receptor, angiotensinogen, AT1 and AT2
Gene Primer sequences for RT–PCR Size of amplified fragments
Renin Sense 50-GTG TCT GTG GGG TCA TCC ACC TTG-30
Antisense 50-GGA TTC CTG AAA TAC ATA GTC CGT-30 243bp
Renin-receptor sense 50-TGT TTT GGG GAA CGA GTT TAG TA-3
Antisense 50-GAG CGT CAA CAA GGA TCT TAG AA-30 691bp
AGT Sense 50-TCC ACC TCG TCA TCC ACA-30
Antisense 50-GGC TCC CAG ATA GAG AGA-30 329bp
AT1 Sense 50-CTT TTC CTG GAT TCC CCA C-30
Antisense 50-CTT CTT GGT GGA TGA GCT TAC-30 304bp
AT2 Sense 50-GTG ACC AAG TCC TGA AGA TG-30
Antisense 50-CAC AAA GGT CTC CAT TTC TC-30 335bp
AGT: angiotensinogen; AT: angiotensin receptor.
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were purchased from Bachem (Bubendorf, Switzerland) and
dissolved in H2O. Pepstatin was purchased from Fluka (Buchs,
Switzerland) and dissolved in methanol. Remikiren (Fischli et al,
1991) and (R)-3-[(3S,4R,5R)-4-[4-[3-(2-methoxy-benzyloxy)-pro-
poxy]-phenyl]-5-(4-methoxy-naphthalen-2-ylmethoxy)-piperidin-
3-ylmethoxy]-propane-1,2-diol (RO0663525} (Breu et al, 2000)
were provided by Hoffmann-LaRoche (Basel, Switzerland). Stock
solution of Remikiren was prepared in H2O and of RO0663525 in
methanol, and then diluted in cell culture medium. The ACE
inhibitors captopril (Sigma, Buchs, Switzerland) and lisinopril (a
gift from Merck, Sharp and Dohme; Juillerat-Jeanneret, 1993) were
dissolved at 10mgml
 1 and diluted in culture medium. The AT2
antagonist PD123319 was purchased from Sigma. LN18 and
LNZ308 human glioblastoma cells (a kind gift of AC Diserens,
CHUV, Lausanne, Switzerland; Diserens et al, 1981) were grown in
DMEM medium containing 4.5gl
 1 glucose and 5% FCS. Cells
were split in 48-well plates and cultured for 1–3 days until
confluence was reached. Peptides or inhibitors were added to the
cells in culture for the time and concentration indicated. Then
either 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium-
bromide (MTT) reduction (cf below) to quantify the number of
metabolically active viable cells, thymidine incorporation (cf
below) to quantify DNA synthesis or measurement of nucleosome
fragments to quantify apoptosis, were performed (cf below).
Experiments were performed in triplicates at least three times and
means7s.d. were calculated.
Evaluation of cell viability, growth and apoptosis
The following techniques were performed as previously described:
cell viability was determined using MTT (Sigma, Buchs, Switzer-
land) reduction and absorbance at 540nm; DNA synthesis using
[
3H]-thymidine (0.2mCiwell
 1; Amersham Pharmacia, Du ¨bendorf,
Switzerland) incorporation (Egidy et al, 2000) and apoptosis was
quantified using the Cell Death Detection ELISA
PLUS (Roche,
Rotkreuz, Switzerland), as previously described (Peduto Eberl et al,
2000).
Protein concentration
Protein content was evaluated with the BCA protein assay kit
(Pierce, Switzerland) according to the manufacturer’s instructions,
using bovine serum albumin as standard.
RESULTS
RT–PCR performed on three different glioblastoma surgical
specimens demonstrated a heterogenous expression of the RAS
components in human glioblastoma. All the three tumours
expressed the mRNAs for renin receptor, AGT and AT1 (two at
low level for this last molecule), two out of three expressed renin
mRNA and one out of three AT2 mRNA (Figure 1). The cellular
localisation of AGT, renin and ACE synthesis in human
glioblastoma was determined by in situ hybridisation (ISH) and
immunohistochemistry (IHC) (Figure 2). AGT mRNA and protein
were expressed by nontumoral astrocytes and glioblastoma cells
(Figure 2A–F). Renin mRNA and protein were highly expressed by
nontumoral neurons (Figure 2G–I), macrophages (not shown;
Juillerat-Jeanneret et al, 2000) and at a lower level by reactive
astrocytes (not shown), and were nonhomogeneously expressed by
tumour cells (Figure 2J–L). High ACE mRNA expression was
found in tumour vessels (Figure 2Q,R), confirming our previous
observation of a high expression of ACE protein in glioblastoma
vasculature by immunohistochemistry (Juillerat-Jeanneret et al,
2000), but only at a very low level in the vessels of nontumoral
tissue (Figure 2N,O). ACE protein was found in tumour-associated
and non-tumoral vessels (Figure 2M,P).
In order to ascertain whether AGT was secreted by human
tumours, its level was determined in human glioblastoma-
associated pseudocyst fluid withdrawn at the time of surgery
(Table 2). For the purpose of comparison, AGT in human
cerebrospinal fluids (CSF) from various brain tumour patients
(n¼13, 0.1770.10mg AGT equivalentml
 1, 0.2370.12 mg
AGTmg
 1 protein) and in human plasma (n¼12, 226.0762.3mg
AGT equivalentml
 1, 3.2371.22 mg AGTmg
 1 protein) was also
123
Renin
Renin-R
AGT
AT1
AT2
Total RNA
335 bp
304 bp
329 bp
691 bp
243 bp
Figure 1 Determination of renin, renin receptor, AGT, AT1 and AT2
mRNAs by RT–PCR performed in three human glioblastoma surgical
samples. RNA extracted from three human glioblastomas was used for
RT–PCR analysis for renin, renin receptor (renin-R), AGT and angiotensin
receptors (AT1 and AT2), using the specific primers described in Table 1.
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from AGT in the presence of added renin and protease inhibitors
to preclude further degradation of Ang I. The results showed that
AGT, but not renin, was present in pseudocyst fluid at concentra-
tions lower than circulating levels but higher than in CSF.
However, the ratio of AGT to total proteins was much higher in
the plasma than in pseudocyst fluid, suggesting that the AGT in
pseudocyst does not result from simple diffusion from plasma.
Thus, the information obtained using these approaches indicated
that the upstream components of the RAS are expressed in tumour
cells of human glioblastoma.
Having established the presence of most of the RAS components
in human glioblastoma, we addressed its role in tumour cells using
the human LN18 and LNZ308 glioblastoma cell lines (Diserens
et al, 1981; Egidy et al, 2000; Juillerat-Jeanneret et al, 2000). Both
cell lines expressed renin, renin receptor, AGT and AT2 mRNAs
using RT–PCR, while only LNZ308 expressed AT1 mRNA
(Figure 3A). Using Western blotting, renin (mainly produced as
prorenin), renin receptor and AT2 proteins were expressed in both
cell lines, while only LNZ308 cells expressed AT1 protein,
corresponding to mRNA expression (Figure 3B). We had
previously shown using an IRMA immunoassay (Juillerat-Jeanner-
et et al, 2000) that renin protein can be measured in cell extracts of
human glioblastoma cells, but not in the culture supernatants. We
have also previously shown that ACE activity is not measurable in
glioblastoma cells in culture (Juillerat-Jeanneret et al, 2000).
Figure 2 ISH and immunohistochemistry for renin, ACE and AGT in human glioblastoma and nontumoral associated tissue. Angiotensinogen (AGT)
(A–F), renin (G–L) and angiotensin-converting enzyme (ACE) (M–R) expression in human glioblastoma (grade IV) (D–F, J–L, P–R) and nontumoral
associated tissue (A–C, G–I, M–O). In situ hybridisation (ISH) (B, C, E, F, H, I, K, L, N, O, Q, R) was performed with the antisense probes for AGT,
renin or ACE, and immunohistochemistry (A, D, G, J, M, P) with antibodies raised against human AGT, renin or ACE. Dark-field (B, E, H, K, N, Q)o r
bright-field illumination of the same tumour areas in consecutive slides. Sense probes or nonrelevant antibodies did not display any signal (not shown).
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the potential to produce AGT, prorenin/renin and Ang I, but not to
convert Ang I into Ang II.
To address the functions of the RAS in human glioblastoma, we
first evaluated the effect of inhibiting renin and ACE in
glioblastoma cells. Three renin inhibitors, pepstatin, remikiren
and RO0663525, at increasing concentrations were used to evaluate
for the functions of renin in glioblastoma cells. While pepstatin
and remikiren had little effect on glioblastoma cells, the addition of
the RO0663525 synthetic renin inhibitor to tumour cells abolished
DNA synthesis after 9h or 24h (Figure 4) (Figure 5A), as well as
decreased the number of viable tumour cells after 24h (Figure 5A).
The presence of FCS did not modify glioblastoma cell response to
the renin inhibitors (Figure 5B). The effect of the RO0663525 renin
inhibitor on DNA synthesis was rapid, since identical inhibition
was obtained after 2 or 8h exposure, indicating that new protein
synthesis was not necessary to obtain this effect (Figure 6).
RO0663525 renin inhibitor induced apoptosis in glioblastoma cells
after 9h exposure, but only in cells previously deprived of FCS for
24h (Figure 7A and B). The ACE inhibitors captopril and lisinopril
did not modulate cell proliferation after 24 or 48h (results not
shown).
Then, we evaluated whether the production of angiotensin
peptides was involved in glioblastoma cell growth, survival and/or
apoptosis. Neither AGT nor Ang II modulated glioblastoma cell
growth, as determined by thymidine incorporation to quantitate
DNA synthesis and MTT reduction to quantitate metabolically
active cells (Figure 8A). Tetradecapeptide renin substrate (TDP/
AGT1-14), Ang I or Ang III comparably to Ang II, even at high
concentration, did not modulate thymidine incorporation
Table 2 Quantification of angiotensinogen in human glioblastoma pseudocyst
Sample Protein (mgml
 1) AGT equivalent (lgAng Iml
 1) Specific activity (lgAGTmg
 1 prot)
A-411 59.5 4.2 0.07
Gbl-747 53.3 4.2 0.08
Gbl-749 50.8 6.1 0.12
Gbl-859 52.8 4.7 0.09
Gbl-920 39.5 4.7 0.11
Gbl-988 59.7 5.2 0.09
Cystic fluids (n¼6) 52.677.4 4.970.7 0.0970.02
A: astrocytome grade II; Gbl: glioblastoma. Pseudocystic fluids (n¼6) were incubated in the presence of added renin and Ang I produced was measured
at the end of the incubation period, providing equivalent AGT. Mean7s.d. values of the combined samples were calculated.
LN 18 LNZ 308
691 bp
335 bp
329 bp
304 bp
243 bp
691 bp
335 bp
329 bp
243 bp
MR RR AGT AT1 AT2 MR RR AGT AT1 AT2
Prorenin
62
47.5
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39.7
39.7
39.7
32.5
LN18
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LN18
LNZ308
LNZ308
LNZ308
LNZ308
Renin
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B
Figure 3 Determination of renin, renin receptor, AGT, AT1 and AT2 in human LN18 and LNZ308 glioblastoma cells. (A) RNA extracted from human
glioblastoma cell lines were used for RT–PCR amplification of renin (R), renin receptor (RR), AGT and angiotensin receptor (AT1 and AT2) mRNAs, using
the specific primers described in Table 1. (B) Proteins extracted from human glioblastoma cell lines were used for Western blotting analysis of the
expression of renin, RR, AT1 and AT2 proteins.
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LNZ308 cells to FasL-induced apoptosis (Table 3). We had
previously shown (Egidy et al, 2000) that LN18 cells are sensitive
to FasL-induced apoptosis, while LNZ308 cells needs sensitisation
to undergo FasL-induced apoptosis. Thus, neither AGT, renin,
TDP, Ang I, nor Ang II, the active hormone of the systemic RAS,
nor Ang III, the predominant peptide produced in human
glioblastoma (Juillerat-Jeanneret et al, 2000), are important in
directly regulating glioblastoma cell growth and/or controlling
apoptosis. Addition of the AT2 antagonist PD123319 to glioblas-
toma cells expressing this receptor did not modify DNA synthesis
(results not shown). Exogenous addition of Ang II or AT1 or AT2
receptor antagonists together with renin inhibitors either did not
counterbalance the growth-inhibitory effects RO0663525 or did not
potentiate Remikiren effects (results not shown). Thus, the active
molecule of the RAS in glioblastoma cells is the enzyme prorenin/
renin, independently of the binding of angiotensin peptides to
their cell-membrane receptors.
DISCUSSION
The expression of renin, AGT, ACE and AT1 receptor in the
developing and normal brain has been previously described. In
normal brain, the main cells expressing AGT are mostly astrocytes
(Humpel et al, 1994), while renin is expressed both by astrocytes
and neuron populations. However, most information has been
obtained in rodents. Renin expression has been previously
demonstrated by immunohistochemistry in human glioblastoma
(Ariza et al, 1988) and AGT synthesis by Northern blotting in
nontumoral (n¼3) and tumoral (n¼3) astrocytic cell lines
(Milsted et al, 1990). In this small series, AGT expression was
higher in normal than tumoral cells, with heterogenous expression
between cells. No expression of renin or ACE was found. ACE is
ubiquitously expressed by the vascular system including brain
vasculature. We have previously shown that human glioblastoma
cell lines did not express ACE activity, but that ACE is highly
expressed in the abnormal vessels of human glioblastoma
(Juillerat-Jeanneret et al, 2000). From this information, it was
postulated that a complete angiotensin system existed in the brain,
independently of the circulating system, and it was assumed that
its role, including in tumours, was important in the regulation of
vascular functions. In the vasculature, AGT, the unique and
specific substrate of renin, was demonstrated to be antiangiogenic
(Ce ´le ´rier et al, 2000, 2002), while angiotensin peptides, in
particular Ang II, were shown to be proangiogenic and to be
involved in vascular growth (Rivera et al, 2001). However, no study
has directly questioned the functions of the RAS, and of its
components, in tumoral astrocytes such as human glioblastoma
cells.
In cancer, the role of the RAS has been mainly evaluated in the
context of vascular functions (Achard et al, 2001). In a C6
glioblastoma rat model, losartan (an AT1 antagonist) reduced
tumour growth, vascular density, tumour cell proliferation and
mitotic index (Rivera et al, 2001). In the present study, we
demonstrate that AGT, prorenin, ACE, AT1 and AT2 are
synthesised and expressed in human glioblastoma and glioblasto-
ma cells in culture, however at different levels of expression
between the specimens. Glioblastoma are highly heterogeneous
tumours. Our results suggest that the expression of the RAS
components varies according to the particular glioblastoma and/or
tumour area, and thus reflects the clonal heterogeneity of
glioblastoma. AGT is released in the tumour pseudocyst in vivo
in humans, and ACE is expressed by tumour-associated vascu-
lature, suggesting a potential production of all RAS components in
the tumour environment.
We addressed first the functions of the angiotensin peptides in
glioblastoma cells. In order to exclude an indirect effect of Ang
peptides transactivating other signaling pathways, we only studied
the effects of these peptides for short time exposure. We showed
that AGT, TDP renin substrate and Ang peptides did not play any
role in glioblastoma cell growth, apoptosis and/or DNA synthesis.
It may be hypothesised from previous information that their
targets, if these peptides are produced by glioblastoma cells, is the
tumour-associated vasculature. These effects involve AT1 recep-
tors, while AT2 receptors may be growth inhibitory and pro-
apoptotic (Berry et al, 2001). AGT and des(Ang I)-AGT have been
shown to be anti-angiogenic (Ce ´le ´rier et al, 2002). Immunohis-
tochemistry for AGT performed on normal tissue, and grade II and
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Figure 4 Renin inhibitors selectively decrease DNA synthesis in human
glioblastoma cells. Cells were grown to confluence in culture medium
containing FCS, then exposed for 24h to different renin inhibitors at
increasing concentrations in fresh medium containing FCS.
3H-thymidine
(
3HT) incorporation to quantify DNA synthesis was performed during the
two last hours of incubation. (A) Pepstatin; (B) remikiren; (C)
RO0663525. ~: LN18 cells; }: LNZ308 cells. Means7s.d. were
calculated.
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yIII astrocytoma and glioblastoma multiform (grade IV) suggested
that the expression of this protein was inversely related to tumour
grading (manuscript in preparation).
We then addressed the effects of inhibiting the enzymes of the
RAS in human glioblastoma. ACE inhibitors may be of some
benefit in cancer (Nakagawa et al, 1995; Reddy et al, 1995; Lever
et al, 1998; Yoshiji et al, 2002), mainly acting via their
antiangiogenic potential and as more general zinc metalloprotease
inhibitors, independently of the RAS and of ACE inhibition. Our
previous experiments with lisinopril and experimental glioblasto-
ma in the rat did not show any benefit in glioblastoma (Juillerat-
Jeanneret et al, 2000); however, we cannot exclude that lisinopril
was not transported across the cerebral vasculature (the blood–
brain barrier), which is not as leaky in experimental rodent models
as in human glioblastoma. In the present study of human
glioblastoma cells in culture, we did not show any effect of the
ACE-inhibitors captopril and lisinopril in cancer cell growth and
DNA synthesis, showing the specificity of ACE inhibitors between
tumour cells of different origins.
However, one renin-selective inhibitor could induce a rapid and
important blockade of DNA synthesis, apoptosis and loss of viable
cells in human glioblastoma cells in culture. This effect of renin
inhibitors seems to depend on the lipophilicity, efficacy (IC50/Ki)
and chemical structure of the compounds, since RO0663525, a
nonpeptidomimetic representative of the piperidine class of
inhibitors (Gu ¨ller et al, 1999; Oefner et al, 1999; Maerki et al,
2001), but not the more hydrophilic peptidomimetics remikiren
and pepstatin, was efficient. Pepstatin is a better inhibitor of
cathepsin D than of renin (Baldwin et al, 1993). Cathepsin D is
more frequently expressed in carcinomas than in connective tissue
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Figure 5 Exposure to RO0663525, but not to remikiren, results in inhibition of DNA synthesis and, concomitantly, a decrease of metabolically active
viable glioblastoma cells. (A) Cells were grown to confluence in culture medium containing FCS, then exposed to renin inhibitors at increasing
concentrations in fresh medium containing FCS either for 9h and
3H-thymidine (
3HT) incorporation to quantify DNA synthesis was performed for the last
two hours of incubation, or for 24h and the number of metabolically active cells was determined using a MTT assay for the last two hours. LN18: m:
RO0663525; n: remikiren; LNZ308: ’: RO0663525; & : remikiren. (B) Cells were grown to confluence in culture medium containing FCS, then either
deprived of FCS for 24h or maintained in FCS-containing medium, and exposed to Remikiren or RO0663525 renin inhibitors at increasing concentrations in
fresh medium containing or not FCS for 9h and
3H-thymidine (
3HT) incorporation to quantify DNA synthesis was performed for the last two hours of
incubation. ~: LN18 cells with FCS; }: LNZ308 cells no FCS; ’: LNZ308 cells with FCS; &: LNZ308 cells no FCS.
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Figure 6 Inhibition of DNA synthesis by RO0663525 is an immediate
effect. Cells were grown to confluence in culture medium containing FCS,
then exposed for 2h or 8h to RO0663525 renin inhibitor at increasing
concentrations in fresh medium containing FCS.
3H-thymidine (
3HT)
incorporation to quantify DNA synthesis was performed during the last
two hours of incubation. LN18: m:2 h ;n: 8h; LNZ308: ’:2 h ,& 8h.
Means7s.d. were calculated.
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yneoplasm such as glioblastoma (Reid et al, 1986); thus an
inhibitory effect on cathepsin D can be excluded. We have
previously shown that human glioblastoma cells do not secrete
renin (Juillerat-Jeanneret et al, 2000). Thus, the inhibitory pattern
of renin inhibitors suggests an intracellular function of prorenin/
renin, and thus only hydrophobic inhibitors have the potential to
inhibit intracellular renin. It has been shown that an alternative
transcription site for renin may be used in the brain, which would
result, if transcribed, in the production of an altered form of
prorenin mRNA, not secreted and constitutively active (Lee-Kirch
et al, 1999; Sinn and Sigmund, 2000). Alternatively, it has been
shown that the binding of piperidine inhibitors to the renin active
site pocket results in an induced structural fit of the enzyme, which
has not been demonstrated for peptidomimetic inhibitors (Deinum
et al, 1998; Vieira et al, 1999; Maerki et al, 2001). This
conformational change may modify the binding of renin/prorenin
to its recently described renin receptor (Nguyen et al, 2002). We
show here that human glioblastoma and glioblastoma cells in
culture express and synthesise the renin receptor. This hormone-
like function of renin/prorenin activates the intracellular signaling
ERK pathways, and survival signalling. We have previously shown
that endothelin receptor antagonists sensitise glioblastoma cells to
Fas-L-induced apoptosis involving the ERK pathway and the
regulation of anti/proapoptotic molecules (Egidy et al, 2000),
raising the possibility of a comparable role for renin/renin-
receptor functions, since we show here that RO0663525 can induce
apoptosis in human glioblastoma cells.
In conclusion, our results suggest that the expression of the RAS
in glioblastoma is heterogeneous and that its functions are double.
First, AGT secreted by astrocytes, whether normal or tumoral cells,
and neuron-derived and vascular-derived renin, ACE and amino-
peptidases will produce angiotensin peptides (Ang I, Ang II, Ang
III). It can be hypothesised from previous information that these
peptides acting through angiotensin receptors on tumour-asso-
ciated vasculature, regulate vascular functions and angiogenesis.
Second, we have shown that renin has a direct role in glioblastoma
cell proliferation and/or survival and that inhibitors of the enzyme
induce a fast and important loss of proliferation and survival of
glioblastoma cells, independent of the action of angiotensin
peptides on their cognate receptors. Two models may explain this
effect: (1) by inducing conformational changes, renin inhibitors
abolish the function of renin on its receptor, activation of the
receptor and intracellular survival signaling; (2) the functions of
renin in glioblastoma cells may be intracellular, and do not involve
cell-membrane-bound angiotensin receptors. These issues need to
be resolved, but renin inhibition, in combination therapy with
other drugs, may be a potential approach to control glioblastoma
progression.
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Figure 7 Induction of apoptosis by RO0663525. Cells were grown to confluence in culture medium containing FCS, then either deprived of FCS for 24h
(A) or maintained in medium with FCS (B), exposed for 9h to RO0663525 renin inhibitor at increasing concentrations in fresh medium without FCS, and
apoptosis index was determined by quantification of nucleosome fragments. Black bars: LN 18 cells; grey bars: LNZ308 cells. Means7s.d. were calculated.
Table 3 Angiotensinogen neither induces apoptosis, nor inhibits or sensitises glioblastoma cells to FasL-induced apoptosis
Apoptosis index
Treatment
% of CHO SN
LN18 LNZ308
(lgAGTml
 1) No FasL 2% FasL No FasL 2% FasL
AGT-CHO cells
0% (0mg AGTml
 1) 1.00 3.55 1.00 1.48
1% (0.15mgml
 1) 1.52 2.65 1.35 2.19
5% (0.75mgml
 1) 2.01 3.92 2.39 1.74
10% (1.50mgml
 1) 1.79 4.88 1.80 1.93
Mock-transfected-CHO cells
0% 1.00 3.55 1.00 1.48
1% 1.66 4.74 1.54 2.03
5% 1.91 5.38 0.96 1.92
10% 1.31 3.28 1.72 2.38
AGT: angiotensinogen. LN18 or LNZ308 cells were treated for 24h in the absence of FCS either with 1–10% of angiotensinogen-containing
supernatant of AGT-transfected CHO cells (0–1.5mg AGTml
 1) or mock-transfected cells, or 2% of FasL-containing supernatant of Neuro2A-FasL
cells or a combination of both. At the end of the incubation period, apoptosis index was quantified by measurement of nucleosome fragments in cells.
Means of duplicate wells were calculated.
Renin and angiotensinogen in brain tumours
L Juillerat-Jeanneret et al
1066
British Journal of Cancer (2004) 90(5), 1059–1068 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yACKNOWLEDGEMENTS
We would like to thank Mrs S Gros, R Bovey, P Fioroni, MT Morin
for excellent technical assistance, Mrs MF Hamou and AC
Diserens, Neurosurgery Division, CHUV, Lausanne, for providing
the cystic fluids and the glioblastoma cell lines, and Dr F Pinet for
helpful information. This work was supported by grants from the
Swiss League and Research against Cancer (SKL 353-9-1996, KFS
947-09-1999 and KFS 1070-09-2000), the Swiss Society for Multiple
Sclerosis and the Swiss National Foundation for Scientific Research
(grant 3200-064907.01).
REFERENCES
Achard JM, Fournier A, Mazouz H, Caride VJ, Penar PL, Fernandez LA
(2001) Protection against ischemia: a physiological function of the
renin–angiotensin system. Biochem Pharm 62: 261–271
Ariza A, Fernandez LA, Inagami T, Kim JH, Manuelidis EE (1988) Renin in
glioblastoma multiform and its role in neovascularization. Am J Clin
Pathol 90: 437–441
B
A
Concentration (nM)
Concentration (nM)
3
H
T
 
[
c
p
m
]
3
H
T
 
(
c
.
p
.
m
.
)
3
H
T
 
[
c
p
m
]
1 20 000
1 00 000
80 000
60 000
40 000
20 000
0
1
0.01 1 100 0
0
0.2
0.4
0.6
0.8
1.2
M
T
T
 
(
A
5
4
0
 
n
m
)
M
T
T
 
(
A
5
4
0
 
n
m
)
100 10 9 8 7 6 5 4 3 2 1 0
0
2000
4000
6000
8000
100 10 9 8 7 6 5 4 3 2 1 0
0
2000
4000
6000
8000
14 000
12 000
10 000
18 000
16 000
14 000
12 000
10 000
LNZ308 cells
LN18 cells
Ang II (nM) LNZ308 LN18
mock mock AGT AGT
0
0.2
0.4
0.6
0.8
1
Figure 8 Angiotensinogen, tetradecapeptide renin substrate (Ang1-14), Ang I, Ang II or Ang III do not modulate glioblastoma cell growth. (A) Left panel:
Confluent cultures of LN18 and LNZ308 cells were deprived of FCS for 24h, then exposed for 48h in the absence of FCS either to 1–10% of AGT-
containing-CHO or mock-transfected cell supernatants in DMEM (black bars: 0%, white bars: 1%, 0.15mg AGTml
 1, light grey bars: 5%, 0.75mg AGTml
 1,
dark grey bars: 10%, 1.5mg AGTml
 1). Right panel: Confluent cultures of LN18 and LNZ308 cells were deprived of FCS for 24h, then either exposed for 7h
to 10
 7,1 0
 9 or 10
 11 M Ang II, and thymidine incorporation was performed for 2h to determine DNA synthesis (
3HT; ~: LN18; n: LNZ308) or exposed
for 24h to 10
 11,1 0
 9 or 10
 7 M Ang II, and MTT reduction was performed to determine the number of metabolically active viable cells (MTT; white bars:
LN18; grey bars: LNZ308). Means7s.d. were calculated. (B) LN18 and LNZ308 cells were grown for 24h to half-confluence in the presence of FCS, then
deprived of FCS for 24h, and exposed for another 24h in the absence of FCS to increasing concentration [0–100nM] of either tetradecapeptide renin
substrate (Ang1–14) (~), Ang I (’), Ang II (m), or Ang III (K) for 24h. Thymidine (
3HT) incorporation was performed during the last two hours to
determine DNA synthesis (
3HT). Means7s.d. were calculated.
Renin and angiotensinogen in brain tumours
L Juillerat-Jeanneret et al
1067
British Journal of Cancer (2004) 90(5), 1059–1068 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yBaldwin ET, Bhat TN, Gulnik S, Hosur MV, Sowder RC, Cachau RE, Collins
J, Silva AM, Erikson JW (1993) Crystal structures of native and inhibited
forms of human cathepsin D: implications for lysosomal targeting and
drug design. Proc Natl Acad Sci USA 90: 6796–6800
Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG (2001) Angiotensin
receptors: signaling, vascular pathophysiology, and interactions with
ceramide. Am J Physiol 281: H2337–H2365
Breu V, Maerki HP, Vieira E, Wostl W (2000) Preparation of piperidine
derivatives as renin inhibitors. PCT Int Appl, 70pp (WO 0064873 A1)
Ce ´le ´rier J, Cruz A, Lamande ´ N, Gasc JM, Corvol P (2002) Angiotensinogen
and its cleaved derivatives inhibit angiogenesis. Hypertension 39:
224–228
Ce ´le ´rier J, Schmid G, Le Caer JP, Gimenez-Roqueplo AP, Bur D, Friedlein A,
Langen H, Corvol P, Jeunemaı ˆtre X (2000) Characterization of a human
angiotensinogen cleaved in its reactive center loop by a proteolytic
activity from Chinese hamster ovary cells. J Biol Chem 275: 10648–10654
Deinum J, Derkx FH, Schalekamp MA (1998) Probing epitopes on human
prorenin during its proteolytic and non-proteolytic activation. Biochim
Biophys Acta 1388: 386–396
De Paepe B, Verstraeten VLMR, De Potter CR, Vakaet LAML, Bullock GR
(2001) Growth stimulatory angiotensin II type-1 receptor in upregulated
in breast hyperplasia and in situ carcinoma but not in invasive
carcinoma. Histochem Cell Biol 116: 247–254
Diserens AC, de Tribollet N, Martin-Achard A, Gaide AC, Schnegg JF,
Carrel S (1981) Characterization of an established human malignant
glioma cell line: LN18. Acta Neuropathol 53: 21–28
Egidy G, Peduto Eberl L, Valdenaire O, Irmler M, Majdi R, Diserens AC,
Fontana A, Janzer RC, Pinet F, Juillerat-Jeanneret L (2000) The
endothelin system in human glioblastoma. Lab Invest 80: 1681–1689
Fischli W, Clozel JP, el Amrani K, Wostl W, Neidhart W, Stadler H, Branca
Q (1991) Ro 42-5892 is a potent orally active renin inhibitor in primates.
Hypertension 18: 22–31
Galen FX, Devaux C, Atlas S, Guyenne T, Me ´nard J, Corvol P, Simon D,
Cazaubon C, Richer P, Badouaille G, Richaud JP, Gros P, Pau B (1984)
New monoclonal antibodies directed against human renin. Powerful
tools for the investigation of the renin system. J Clin Invest 74: 723–735
Gu ¨ller R, Binggeli A, Breu V, Bur D, Fischli W, Hirth G, Jenny C, Kansy M,
Montavon F, Mu ¨ller M, Oefner C, Stadler H, Vieira E, Wilhelm M,
Wostl W, Ma ¨rki HP (1999) Piperidine-renin inhibitors: compounds
with improved physicochemical properties. Bioorg Med Chem Lett 9:
1403–1408
Hirasawa K, Sato Y, Hosoda Y, Yamamoto T, Hanai H (2002)
Immunohistochemical localization of angiotensin II receptor and local
renin–angiotensin system in human colonic mucosa. J Histochem
Cytochem 50: 275–282
Humpel C, Lippoldt A, Stro ¨mberg I, Bygdeman M, Wagner J, Hilgenfeldt U,
Ganten D, Fuxe K, Olson L (1994) Human angiotensinogen is highly
expressed in human cortical grafts. Glia 10: 186–192
Inwang ER, Puddefoot JR, Brown CL, Goode AW, Marsigliante S, Ho MM,
Payne JG, Vinson GP (1997) Angiotensin II type 1 receptor expression in
human breast tissue. Br J Cancer 75: 1279–1283
Juillerat-Jeanneret L (1993) Modulation of proteolytic activity in tissues
following chronic inhibition of angiotensin converting enzyme. Biochem
Pharm 45: 1447–1454
Juillerat-Jeanneret L, Lohm S, Hamou MF, Pinet F (2000) Regulation of
aminopeptidase A in human brain tumor vasculature: evidence for a role
of transforming growth factor-b. Lab Invest 80: 973–980
Kakinuma Y, Hama H, Sugiyama F, Goto K, Murakami K, Fukamizu A
(1997) Anti-apoptotic action of angiotensin fragments to neuronal cells
from angiotensinogen knock-out mice. Neurosci Lett 232: 167–170
Lee-Kirch MA, Gaudet F, Cardoso MC, Lindpaintner K (1999) Distinct
renin isoforms generated by tissue-specific transcription initiation and
alternative splicing. Circ Res 84: 240–246
Lever AF, Hole DJ, Gillis CR, McCallum IR, MacKinnon PL, Meredith PL,
Murray LS, Reid JL, Robertson JW (1998) Do inhibitors of angiotensin-I-
converting enzyme protects against risk of cancer? Lancet 352:
179–184
Maerki HP, Binggeli A, Bittner B, Bohner-Lang V, Breu V, Bur D, Coassolo
PH, Clozel JP, D’Arcy A, Doebeli H, Fischli W, Funk CH, Foricher J,
Giller T, Gruninger F, Guenzi A, Guller R, Hartung T, Hirth G, Jenny CH,
Kansy M, Klinkhammer U, Lave T, Lohri B, Luft FC, Mervaala EM,
Muller DN, Muller M, Montavon F, Oefner CH, Qiu C, Reichel A,
Sanwald-Ducray P, Scalone M, Schleimer M, Schmid R, Stadler H,
Treiber A, Valdenaire O, Vieira E, Waldmeier P, Wiegand-Chou R,
Wilhelm M, Wostl W, Zell M, Zell R (2001) Piperidine renin inhibitors:
from leads to drug candidates. Il Farmaco 56: 21–27
Milsted A, Barna BP, Ransohoff RM, Brosnihan KB, Ferrario CM (1990)
Astrocyte cultures derived from human brain tissue express angiotensi-
nogen mRNA. Proc Natl Acad Sci USA 87: 5720–5723
Morimoto S, Cassell MD, Sigmund CD (2002) Glia- and neuron-specific
expression of the renin–angiotensin system in brain alters blood
pressure, water intake, and salt preference. J Biol Chem 277:
33235–33241
Nakagawa T, Kubota T, Kabuto M, Kodera T (1995) Captopril inhibits
glioma cell invasion in vitro: involvement of matrix metalloproteinases.
Anticancer Res 15: 1985–1989
Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD (1996) Specific
receptor binding of renin on human mesangial cells in culture increases
plasminogen activator inhibitor-1 antigen. Kidney Int 50: 1897–1903
Nguyen G, Delarue F, Burckle ´ C, Bouzhir L, Giller T, Sraer JD (2002) Pivotal
role of the renin/prorenin receptor in angiotensin II production and
cellular response to renin. J Clin Invest 109: 1417–1427
Oefner C, Binggeli A, Breu V, Bur D, Clozel JP, D’Arcy A, Dorn A, Fischli
W, Gru ¨ninger F, Gu ¨ller R, Hirth G, Ma ¨rki HP, Mathews S, Mu ¨ller M,
Ridley RG, Stadler H, Vieira E, Wilhelm M, Winkler FK, Wostl W
(1999) Renin inhibition by substituted piperidines: a novel paradigm
for the inhibition of monomeric aspartic proteinases? Chem Biol 6:
127–131
Peduto Eberl L, Valdenaire O, SaintGiorgio V, Jeannin JF, Juillerat-
Jeanneret L (2000) Endothelin receptor blockade potentiates FasL-
induced apoptosis in rat colon carcinoma cells. Int J Cancer 86: 182–187
Reddy MK, Baskaran K, Molteni A (1995) Inhibitors of angiotensin-
converting enzyme modulate mitosis and gene expression in pancreatic
cancer cells. Proc Natl Acad Sci USA 210: 221–226
Reid WA, Valler MJ, Kay J (1986) Immunolocalization of cathepsin D in
normal and neoplastic human tissues. J Clin Pathol 39: 1323–1330
Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J (2001) AT1 receptor
is present in glioma cells, its blockage reduces the growth of rat glioma.
Br J Cancer 85: 1396–1399
Sibony M, Commo F, Callard P, Gasc JM (1995) Enhancement of mRNA in
situ hybridization signal by microwave heating. Lab Invest 73: 586–591
Sinn PL, Sigmund CD (2000) Identification of three human renin mRNA
isoforms from alternative tissue-specific transcriptional initiation.
Physiol Genomics 3: 25–31
Tahmasebi M, Puddefoot JR, Inwang ER, Goode AW, Carpenter R, Vinson
GP (1998) Transcription of the prorenin gene in normal and diseased
breast. Eur J Cancer 34: 1777–1782
Takahashi S, Miura R, Miyake Y (1985) A study of renin binding protein
(RnBP) in the human kidney. J Biochem 97: 671–677
Vieira E, Binggeli A, Breu V, Bur D, Fischli W, Gu ¨ller R, Hirth G,
Ma ¨rki HP, Mu ¨ller M, Oefner C, Scalone M, Stadler H, Wilhelm M, Wostl
W (1999) Substituted piperidines. Highly potent renin inhibitors
due to induced fit adaptation of the active site. Bioorg Med Chem Lett
9: 1397–1402
Yoshiji H, Kuriyama S, Fukui H (2002) Perindopril: possible use in cancer
therapy. Anti-cancer drugs 13: 221–228
Renin and angiotensinogen in brain tumours
L Juillerat-Jeanneret et al
1068
British Journal of Cancer (2004) 90(5), 1059–1068 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y